BelarusTuberculosis profile
Population  2016 9.5 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.23 (0.2–0.26) 2.4 (2.1–2.8)
Mortality (HIV+TB only) 0.13 (0.086–0.17) 1.3 (0.91–1.8)
Incidence  (includes HIV+TB) 4.9 (3.5–6.5) 52 (37–69)
Incidence (HIV+TB only) 0.4 (0.26–0.57) 4.2 (2.7–6)
Incidence (MDR/RR-TB)** 3.4 (2.6–4.1) 35 (28–43)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.27 (0.19–0.35) 1.2 (0.86–1.6) 1.5 (1–2)
Males 0.3 (0.21–0.4) 3.1 (2.2–4.1) 3.4 (2.4–4.5)
Total 0.57 (0.4–0.74) 4.4 (3–5.7) 4.9 (3.5–6.5)
TB case notifications, 2016  
Total cases notified 3 598
Total new and relapse 3 211
          - % tested with rapid diagnostics at time of diagnosis 80%
          - % with known HIV status 98%
          - % pulmonary 92%
          - % bacteriologically confirmed among pulmonary 79%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 65% (49–91)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.07 (0.05–0.1)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 275 9%
          - on antiretroviral therapy 229 83%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 600
(1 500–1 600)
Estimated % of TB cases with MDR/RR-TB 38% (36–40) 72% (68–75)  
% notified tested for rifampicin resistance 70% 89% 2 701
MDR/RR-TB cases tested for resistance to second-line drugs   1 222
Laboratory-confirmed cases MDR/RR-TB: 1 543, XDR-TB: 572
Patients started on treatment **** MDR/RR-TB: 1 362, XDR-TB: 572
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 89% 2 525
Previously treated cases, excluding relapse, registered in 2015 76% 263
HIV-positive TB cases registered in 2015 79% 113
MDR/RR-TB cases started on second-line treatment in 2014 59% 1 472
XDR-TB cases started on second-line treatment in 2014 36% 431
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment <1%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions) 12
Funding source: 43% domestic, 27% international, 30% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-20 Data: www.who.int/tb/data